Literature DB >> 35719875

A Brief Introduction to Human Behavioral Pharmacology: Methods, Design Considerations and Ethics.

William W Stoops1.   

Abstract

Human behavioral pharmacology methods have been used to rigorously evaluate the effects of a range of centrally acting drugs in humans under controlled conditions for decades. Methods like drug self-administration and drug discrimination have been adapted from nonhuman laboratory animal models. Because humans have the capacity to communicate verbally, self-report methods are also commonly used to understand drug effects. This perspective article provides an overview of these traditional human behavioral pharmacology methods and introduces some novel methodologies that have more recently been adapted for use in the field. Design (e.g., using placebo controls, testing multiple doses) and ethical (e.g., avoiding enrollment of individuals seeking treatment, determining capacity to consent) considerations that must be addressed when conducting these types of studies are also described. © Association for Behavior Analysis International 2022.

Entities:  

Keywords:  Behavior; Discriminative stimulus effects; Human; Pharmacology; Reinforcing effects; Subjective effects

Year:  2022        PMID: 35719875      PMCID: PMC9163231          DOI: 10.1007/s40614-022-00330-5

Source DB:  PubMed          Journal:  Perspect Behav Sci        ISSN: 2520-8969


  106 in total

1.  Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects.

Authors:  Thomas F Newton; Richard De La Garza; Ari D Kalechstein; Liam Nestor
Journal:  Pharmacol Biochem Behav       Date:  2005-08-19       Impact factor: 3.533

Review 2.  Assessing abuse liability during drug development: changing standards and expectations.

Authors:  K A Schoedel; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  2008-01-23       Impact factor: 6.875

3.  The history of a public science: How the Addiction Research Center became the NIDA Intramural Research Program.

Authors:  Nancy D Campbell
Journal:  Drug Alcohol Depend       Date:  2010-02-01       Impact factor: 4.492

Review 4.  Excessive discounting of delayed reinforcers as a trans-disease process: Update on the state of the science.

Authors:  Warren K Bickel; Liqa N Athamneh; Julia C Basso; Alexandra M Mellis; William B DeHart; William H Craft; Derek Pope
Journal:  Curr Opin Psychol       Date:  2019-02-06

5.  Modafinil decreases cocaine choice in human cocaine smokers only when the response requirement and the alternative reinforcer magnitude are large.

Authors:  Richard W Foltin; Margaret Haney; Gillinder Bedi; Suzette M Evans
Journal:  Pharmacol Biochem Behav       Date:  2016-09-01       Impact factor: 3.533

6.  Substance use after participation in laboratory studies involving smoked cocaine self-administration.

Authors:  Raj K Kalapatapu; Gillinder Bedi; Margaret Haney; Suzette M Evans; Eric Rubin; Richard W Foltin
Journal:  Drug Alcohol Depend       Date:  2011-08-15       Impact factor: 4.492

Review 7.  Pharmacological challenge studies with acute psychosocial stress.

Authors:  Kathryne Van Hedger; Anya K Bershad; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2017-08-22       Impact factor: 4.905

Review 8.  Principles of initial experimental drug abuse liability assessment in humans.

Authors:  Roland R Griffiths; George E Bigelow; Nancy A Ator
Journal:  Drug Alcohol Depend       Date:  2003-06-05       Impact factor: 4.492

9.  Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors.

Authors:  Takato Hiranita; Paul L Soto; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-02-19       Impact factor: 4.030

10.  The effectiveness of attentional bias modification for substance use disorder symptoms in adults: a systematic review.

Authors:  Janika Heitmann; Elise C Bennik; Madelon E van Hemel-Ruiter; Peter J de Jong
Journal:  Syst Rev       Date:  2018-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.